GITNUXREPORT 2026

Obesity Drug Industry Statistics

The obesity drug industry is growing exponentially, driven by effective GLP-1 medications.

Jannik Lindner

Co-Founder of Gitnux, specialized in content and tech since 2016.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Statistic 1

Semaglutide (Wegovy/Ozempic) weight loss of 15% body weight at 68 weeks in STEP 1 trial (n=1961).

Statistic 2

Tirzepatide achieved 20.9% weight loss vs 3.1% placebo at 72 weeks in SURMOUNT-1 (n=2539).

Statistic 3

STEP 5 trial: Semaglutide 2.4mg maintained 17.4% weight loss over 104 weeks vs 2% regain with placebo.

Statistic 4

Tirzepatide 15mg led to 22.5% weight reduction at 72 weeks in SURMOUNT-2 for T2D patients (n=938).

Statistic 5

Retatrutide triple agonist showed 24.2% weight loss at 48 weeks in Phase 2 (n=338).

Statistic 6

CagriSema combo achieved 22.7% weight loss at 68 weeks vs 15.1% semaglutide alone (n=832).

Statistic 7

VK2735 subcutaneous weekly dosing resulted in 13.1% weight loss at 13 weeks Phase 2 (n=176).

Statistic 8

Oral VK2735 showed 5.3% placebo-adjusted weight loss at 28 days Phase 2a (n=136).

Statistic 9

MariTide (AMG 133) achieved 14.5% weight loss at 12 weeks Phase 1b (n=32).

Statistic 10

Pemvidutide 2.4mg led to 10.9% weight loss at 48 weeks Phase 2 MOMENTUM (n=428).

Statistic 11

GSBR-1290 oral GLP-1 showed 6.2% weight loss at 12 weeks Phase 2a (n=84).

Statistic 12

Orforglipron oral showed 14.7% weight loss at 36 weeks Phase 2 (n=272).

Statistic 13

Survodutide 4.8mg achieved 19% weight loss at 46 weeks Phase 2 (n=415).

Statistic 14

Mazdutide 9mg led to 15.4% weight loss at 48 weeks Phase 3 (n=963).

Statistic 15

Semaglutide improved HbA1c by 1.6% alongside 14.9% weight loss in STEP 2 (n=1210).

Statistic 16

Tirzepatide reduced cardiovascular risk markers by 20% in SURPASS trials.

Statistic 17

STEP-HFpEF: Semaglutide 13.3% weight loss, improved symptoms (n=529).

Statistic 18

SURMOUNT-3: Tirzepatide 26.6% total weight loss after lifestyle intervention.

Statistic 19

SELECT CVOT: Semaglutide 20% CV risk reduction, 9.4% weight loss (n=17,604).

Statistic 20

SURMOUNT-4: Tirzepatide maintenance 25.3% sustained loss vs regain.

Statistic 21

Amycretin oral Novo: 13.1% weight loss 12 weeks Phase 1 (n=36).

Statistic 22

CT-388 (dual agonist) 19.7% weight loss 12 weeks Phase 1b.

Statistic 23

Bimagrumab + semaglutide 21% weight loss, preserved muscle Phase 2.

Statistic 24

Ecnoglutide 9mg 15% weight loss 24 weeks Phase 2 China.

Statistic 25

20.4% weight loss with semaglutide in adolescents STEP TEENS (n=201).

Statistic 26

Tirzepatide 17.8% weight loss in T2D SURMOUNT-5 head-to-head.

Statistic 27

Novo Nordisk's Wegovy generated $4.5 billion in global sales in 2023, representing 18% of company revenue.

Statistic 28

Eli Lilly's Zepbound sales reached $517.4 million in Q4 2023 alone, with full-year tirzepatide at $2.2 billion.

Statistic 29

Ozempic sales for Novo Nordisk hit $13.9 billion in 2023, up 60% from 2022.

Statistic 30

Mounjaro (tirzepatide) generated $5.1 billion for Lilly in 2024 H1, driven by obesity labeling.

Statistic 31

Wegovy U.S. sales alone were $2.6 billion in H1 2024 for Novo Nordisk.

Statistic 32

Pfizer's obesity drug pipeline contributed $0 revenue in 2023 but projected $10B peak sales for danuglipron.

Statistic 33

Viking Therapeutics' VK2735 projected peak sales of $8-10 billion annually if approved.

Statistic 34

Structure Therapeutics' GSBR-1290 expected to generate $5 billion peak sales.

Statistic 35

Amgen's MariTide projected $2.7 billion peak annual sales by analysts.

Statistic 36

Roche's CT-996 oral GLP-1 projected $3 billion peak sales post-Phase 2 success.

Statistic 37

Altimmune's pemvidutide forecasted $4 billion U.S. peak sales.

Statistic 38

Novo Nordisk's CagriSema projected peak sales exceeding $20 billion annually.

Statistic 39

Eli Lilly's retatrutide Phase 3 trials support $15 billion peak sales estimate.

Statistic 40

Total GLP-1 market sales reached $28 billion globally in 2023.

Statistic 41

U.S. GLP-1 prescriptions generated $18.5 billion in patient spend in 2023.

Statistic 42

Novo H1 2024 GLP-1 sales $12.9B, up 24% YoY.

Statistic 43

Lilly Q2 2024 Mounjaro/Zepbound sales $3B combined.

Statistic 44

Ozempic 2024 full year guidance $19-20B for Novo.

Statistic 45

Total obesity franchise $8B for Lilly in 2024 projection.

Statistic 46

Pfizer discontinued oral danuglipron, pivot to once-daily.

Statistic 47

Zealand Pharma survodutide partnership with Boehringer, $4.5B potential milestones.

Statistic 48

Hanmi Pham's HM15211 projected $6B peak sales.

Statistic 49

Regeneron TREK-1/2 inhibitors early stage, $5B potential.

Statistic 50

The global obesity drug market was valued at approximately $3.07 billion in 2023 and is projected to reach $134.85 billion by 2035, growing at a CAGR of 28.4%.

Statistic 51

In 2023, North America dominated the anti-obesity drugs market with a share of 46.7%, driven by high obesity prevalence and drug approvals.

Statistic 52

The GLP-1 receptor agonist segment is expected to hold 65% of the obesity drug market revenue by 2030 due to drugs like semaglutide and tirzepatide.

Statistic 53

Asia-Pacific obesity drug market is forecasted to grow at the highest CAGR of 24.5% from 2024 to 2032, fueled by rising obesity rates in China and India.

Statistic 54

By 2028, the U.S. obesity treatment market is projected to exceed $50 billion, with GLP-1 drugs accounting for 80% of new prescriptions.

Statistic 55

The combination therapy segment in obesity drugs is anticipated to grow from $1.2 billion in 2023 to $15.6 billion by 2032 at a CAGR of 33.2%.

Statistic 56

Europe anti-obesity market reached €1.8 billion in 2023, with projections to €12.5 billion by 2030 at 31% CAGR.

Statistic 57

Oral semaglutide market for obesity is expected to capture 25% share by 2030, valued at $20 billion globally.

Statistic 58

The pediatric obesity drug market segment is projected to grow at 26.8% CAGR from 2024-2032, reaching $4.5 billion.

Statistic 59

By 2030, digital therapeutics integrated with obesity drugs could add $10 billion to the market.

Statistic 60

Latin America obesity drug market valued at $450 million in 2023, expected to hit $3.2 billion by 2031 at 28% CAGR.

Statistic 61

Middle East & Africa segment to grow from $300 million in 2023 to $2.1 billion by 2032 at 24.1% CAGR.

Statistic 62

Bariatric surgery market complementing drugs valued at $6.5 billion in 2023, but drugs projected to overtake with 35% CAGR.

Statistic 63

Biosimilars for GLP-1 drugs expected to enter market by 2032, reducing costs by 40% and expanding access.

Statistic 64

Home delivery of obesity drugs projected to be 40% of market by 2028, valued at $25 billion.

Statistic 65

U.S. obesity drug market share: Novo Nordisk 55%, Lilly 35%, others 10% in 2023.

Statistic 66

Projected $100 billion U.S. obesity drug spend by 2030, per JPMorgan.

Statistic 67

GLP-1 agonists to represent 50% of new anti-diabetic scripts by 2025.

Statistic 68

China obesity drug market $1.5B in 2023, CAGR 45% to 2030.

Statistic 69

Biosimilar semaglutide entry 2032 could cut prices 30-50%.

Statistic 70

Digital health apps bundled with drugs: 20% market penetration by 2028.

Statistic 71

U.S. new GLP-1 prescriptions for obesity reached 12 million in 2023.

Statistic 72

15% of U.S. adults used GLP-1 drugs for weight loss in 2024 surveys.

Statistic 73

Wegovy prescriptions grew 300% YoY to 1.2 million monthly in U.S. Q2 2024.

Statistic 74

36% of Zepbound scripts from new patients in Q1 2024 per Lilly.

Statistic 75

Off-label Ozempic use for obesity: 70% of total prescriptions in 2023.

Statistic 76

Average treatment duration 8 months for GLP-1 obesity drugs, 50% discontinue.

Statistic 77

9 million U.S. adults forecasted to use GLP-1s for obesity by 2028.

Statistic 78

Women represent 75% of obesity drug prescribers' patients.

Statistic 79

Medicare Part D GLP-1 spending $5.7 billion in 2023 for obesity-related claims.

Statistic 80

Compounded semaglutide prescriptions: 2.5 million in U.S. 2023, 50% cheaper.

Statistic 81

UK NICE approved semaglutide for 2.9 million obese adults, 490,000 start in year 1.

Statistic 82

Canada obesity drug prescriptions up 400% since 2022 to 1.2 million annually.

Statistic 83

Employer-sponsored insurance covered GLP-1s for 40% of obese employees by 2024.

Statistic 84

Pediatric prescriptions for GLP-1s rose 400% from 2021-2023 (n=1,000 to 4,300).

Statistic 85

Global obesity drug adherence rate 55% at 12 months per meta-analysis.

Statistic 86

28% U.S. adults with obesity interested in GLP-1 drugs per KFF poll.

Statistic 87

1 in 8 U.S. adults tried GLP-1s by 2024, Gallup.

Statistic 88

Shortage resolved for Wegovy Q3 2024, prescriptions up 70%.

Statistic 89

Lilly Zepbound weekly scripts 150,000 in launch month Dec 2023.

Statistic 90

Semaglutide nausea incidence 44% vs 17% placebo in STEP trials.

Statistic 91

Tirzepatide GI side effects: 25% discontinuation rate due to adverse events in SURMOUNT-1.

Statistic 92

FDA reported 36 cases of ileus with semaglutide/tirzepatide as of Oct 2023.

Statistic 93

Wegovy label warns of 1.6% pancreatitis risk vs 0.9% placebo in trials.

Statistic 94

Tirzepatide thyroid C-cell tumors in rodents, boxed warning on Zepbound label.

Statistic 95

13 deaths reported in obesity drug users per WHO database up to 2023.

Statistic 96

Muscle loss 40% of total weight loss with GLP-1s, per JAMA study (n=226).

Statistic 97

Gallbladder events 1.6% with semaglutide vs 0.7% placebo in SELECT trial.

Statistic 98

Vision changes (retinopathy) 0.5% higher with tirzepatide in T2D trials.

Statistic 99

Hypoglycemia risk low at 0.6% with tirzepatide monotherapy.

Statistic 100

FDA adverse event reports for semaglutide exceeded 100,000 by mid-2024.

Statistic 101

Tachycardia (heart rate increase >10bpm) in 20% of VK2735 Phase 2 patients.

Statistic 102

Pemvidutide liver enzyme elevations in 5% of patients at higher doses.

Statistic 103

Orforglipron GI AEs led to 10% discontinuation in Phase 2.

Statistic 104

Survodutide injection site reactions 15% vs 5% placebo.

Statistic 105

Gastroparesis reports doubled with GLP-1 use per FDA FAERS 2023.

Statistic 106

Suicidal ideation signals in 0.2% semaglutide users, EMA review.

Statistic 107

Hair loss reported in 3% of GLP-1 users in real-world data.

Statistic 108

Fatigue 20% incidence with tirzepatide initiation.

Statistic 109

Renal impairment risk 0.4% higher with semaglutide in CKD patients.

1/109

Sources

Trusted by 500+ publications

+497

Imagine a single pill that could shrink a patient's waistline and expand a market from $3 billion to over $134 billion in just over a decade, and you begin to grasp the staggering economic and medical force of the modern obesity drug industry.

Key Takeaways

The global obesity drug market was valued at approximately $3.07 billion in 2023 and is projected to reach $134.85 billion by 2035, growing at a CAGR of 28.4%.
In 2023, North America dominated the anti-obesity drugs market with a share of 46.7%, driven by high obesity prevalence and drug approvals.
The GLP-1 receptor agonist segment is expected to hold 65% of the obesity drug market revenue by 2030 due to drugs like semaglutide and tirzepatide.
Novo Nordisk's Wegovy generated $4.5 billion in global sales in 2023, representing 18% of company revenue.
Eli Lilly's Zepbound sales reached $517.4 million in Q4 2023 alone, with full-year tirzepatide at $2.2 billion.
Ozempic sales for Novo Nordisk hit $13.9 billion in 2023, up 60% from 2022.
Semaglutide (Wegovy/Ozempic) weight loss of 15% body weight at 68 weeks in STEP 1 trial (n=1961).
Tirzepatide achieved 20.9% weight loss vs 3.1% placebo at 72 weeks in SURMOUNT-1 (n=2539).
STEP 5 trial: Semaglutide 2.4mg maintained 17.4% weight loss over 104 weeks vs 2% regain with placebo.
Semaglutide nausea incidence 44% vs 17% placebo in STEP trials.
Tirzepatide GI side effects: 25% discontinuation rate due to adverse events in SURMOUNT-1.
FDA reported 36 cases of ileus with semaglutide/tirzepatide as of Oct 2023.
U.S. new GLP-1 prescriptions for obesity reached 12 million in 2023.
15% of U.S. adults used GLP-1 drugs for weight loss in 2024 surveys.
Wegovy prescriptions grew 300% YoY to 1.2 million monthly in U.S. Q2 2024.

The obesity drug industry is growing exponentially, driven by effective GLP-1 medications.

Clinical Trial Efficacy Data

Semaglutide (Wegovy/Ozempic) weight loss of 15% body weight at 68 weeks in STEP 1 trial (n=1961).
Tirzepatide achieved 20.9% weight loss vs 3.1% placebo at 72 weeks in SURMOUNT-1 (n=2539).
STEP 5 trial: Semaglutide 2.4mg maintained 17.4% weight loss over 104 weeks vs 2% regain with placebo.
Tirzepatide 15mg led to 22.5% weight reduction at 72 weeks in SURMOUNT-2 for T2D patients (n=938).
Retatrutide triple agonist showed 24.2% weight loss at 48 weeks in Phase 2 (n=338).
CagriSema combo achieved 22.7% weight loss at 68 weeks vs 15.1% semaglutide alone (n=832).
VK2735 subcutaneous weekly dosing resulted in 13.1% weight loss at 13 weeks Phase 2 (n=176).
Oral VK2735 showed 5.3% placebo-adjusted weight loss at 28 days Phase 2a (n=136).
MariTide (AMG 133) achieved 14.5% weight loss at 12 weeks Phase 1b (n=32).
Pemvidutide 2.4mg led to 10.9% weight loss at 48 weeks Phase 2 MOMENTUM (n=428).
GSBR-1290 oral GLP-1 showed 6.2% weight loss at 12 weeks Phase 2a (n=84).
Orforglipron oral showed 14.7% weight loss at 36 weeks Phase 2 (n=272).
Survodutide 4.8mg achieved 19% weight loss at 46 weeks Phase 2 (n=415).
Mazdutide 9mg led to 15.4% weight loss at 48 weeks Phase 3 (n=963).
Semaglutide improved HbA1c by 1.6% alongside 14.9% weight loss in STEP 2 (n=1210).
Tirzepatide reduced cardiovascular risk markers by 20% in SURPASS trials.
STEP-HFpEF: Semaglutide 13.3% weight loss, improved symptoms (n=529).
SURMOUNT-3: Tirzepatide 26.6% total weight loss after lifestyle intervention.
SELECT CVOT: Semaglutide 20% CV risk reduction, 9.4% weight loss (n=17,604).
SURMOUNT-4: Tirzepatide maintenance 25.3% sustained loss vs regain.
Amycretin oral Novo: 13.1% weight loss 12 weeks Phase 1 (n=36).
CT-388 (dual agonist) 19.7% weight loss 12 weeks Phase 1b.
Bimagrumab + semaglutide 21% weight loss, preserved muscle Phase 2.
Ecnoglutide 9mg 15% weight loss 24 weeks Phase 2 China.
20.4% weight loss with semaglutide in adolescents STEP TEENS (n=201).
Tirzepatide 17.8% weight loss in T2D SURMOUNT-5 head-to-head.

Clinical Trial Efficacy Data Interpretation

The obesity drug industry has evolved from a fringe pursuit into a serious heavyweight, with competitors now consistently landing double-digit percentage body weight losses that would have been dismissed as science fiction just a decade ago.

Company Sales & Revenue

Novo Nordisk's Wegovy generated $4.5 billion in global sales in 2023, representing 18% of company revenue.
Eli Lilly's Zepbound sales reached $517.4 million in Q4 2023 alone, with full-year tirzepatide at $2.2 billion.
Ozempic sales for Novo Nordisk hit $13.9 billion in 2023, up 60% from 2022.
Mounjaro (tirzepatide) generated $5.1 billion for Lilly in 2024 H1, driven by obesity labeling.
Wegovy U.S. sales alone were $2.6 billion in H1 2024 for Novo Nordisk.
Pfizer's obesity drug pipeline contributed $0 revenue in 2023 but projected $10B peak sales for danuglipron.
Viking Therapeutics' VK2735 projected peak sales of $8-10 billion annually if approved.
Structure Therapeutics' GSBR-1290 expected to generate $5 billion peak sales.
Amgen's MariTide projected $2.7 billion peak annual sales by analysts.
Roche's CT-996 oral GLP-1 projected $3 billion peak sales post-Phase 2 success.
Altimmune's pemvidutide forecasted $4 billion U.S. peak sales.
Novo Nordisk's CagriSema projected peak sales exceeding $20 billion annually.
Eli Lilly's retatrutide Phase 3 trials support $15 billion peak sales estimate.
Total GLP-1 market sales reached $28 billion globally in 2023.
U.S. GLP-1 prescriptions generated $18.5 billion in patient spend in 2023.
Novo H1 2024 GLP-1 sales $12.9B, up 24% YoY.
Lilly Q2 2024 Mounjaro/Zepbound sales $3B combined.
Ozempic 2024 full year guidance $19-20B for Novo.
Total obesity franchise $8B for Lilly in 2024 projection.
Pfizer discontinued oral danuglipron, pivot to once-daily.
Zealand Pharma survodutide partnership with Boehringer, $4.5B potential milestones.
Hanmi Pham's HM15211 projected $6B peak sales.
Regeneron TREK-1/2 inhibitors early stage, $5B potential.

Company Sales & Revenue Interpretation

The staggering gold rush in obesity drugs, where current blockbusters are minting billions and the pipeline promises trillions, reveals an industry betting heavily that our collective waistlines are the new pharmaceutical frontier.

Market Size & Projections

The global obesity drug market was valued at approximately $3.07 billion in 2023 and is projected to reach $134.85 billion by 2035, growing at a CAGR of 28.4%.
In 2023, North America dominated the anti-obesity drugs market with a share of 46.7%, driven by high obesity prevalence and drug approvals.
The GLP-1 receptor agonist segment is expected to hold 65% of the obesity drug market revenue by 2030 due to drugs like semaglutide and tirzepatide.
Asia-Pacific obesity drug market is forecasted to grow at the highest CAGR of 24.5% from 2024 to 2032, fueled by rising obesity rates in China and India.
By 2028, the U.S. obesity treatment market is projected to exceed $50 billion, with GLP-1 drugs accounting for 80% of new prescriptions.
The combination therapy segment in obesity drugs is anticipated to grow from $1.2 billion in 2023 to $15.6 billion by 2032 at a CAGR of 33.2%.
Europe anti-obesity market reached €1.8 billion in 2023, with projections to €12.5 billion by 2030 at 31% CAGR.
Oral semaglutide market for obesity is expected to capture 25% share by 2030, valued at $20 billion globally.
The pediatric obesity drug market segment is projected to grow at 26.8% CAGR from 2024-2032, reaching $4.5 billion.
By 2030, digital therapeutics integrated with obesity drugs could add $10 billion to the market.
Latin America obesity drug market valued at $450 million in 2023, expected to hit $3.2 billion by 2031 at 28% CAGR.
Middle East & Africa segment to grow from $300 million in 2023 to $2.1 billion by 2032 at 24.1% CAGR.
Bariatric surgery market complementing drugs valued at $6.5 billion in 2023, but drugs projected to overtake with 35% CAGR.
Biosimilars for GLP-1 drugs expected to enter market by 2032, reducing costs by 40% and expanding access.
Home delivery of obesity drugs projected to be 40% of market by 2028, valued at $25 billion.
U.S. obesity drug market share: Novo Nordisk 55%, Lilly 35%, others 10% in 2023.
Projected $100 billion U.S. obesity drug spend by 2030, per JPMorgan.
GLP-1 agonists to represent 50% of new anti-diabetic scripts by 2025.
China obesity drug market $1.5B in 2023, CAGR 45% to 2030.
Biosimilar semaglutide entry 2032 could cut prices 30-50%.
Digital health apps bundled with drugs: 20% market penetration by 2028.

Market Size & Projections Interpretation

The global obesity drug market, once a niche sector valued at a few billion dollars, is ballooning into a behemoth projected to exceed $130 billion in little over a decade, as society essentially invests in pharmaceutical tailors to take in the world's ever-expanding waistline.

Prescriptions & Patient Usage

U.S. new GLP-1 prescriptions for obesity reached 12 million in 2023.
15% of U.S. adults used GLP-1 drugs for weight loss in 2024 surveys.
Wegovy prescriptions grew 300% YoY to 1.2 million monthly in U.S. Q2 2024.
36% of Zepbound scripts from new patients in Q1 2024 per Lilly.
Off-label Ozempic use for obesity: 70% of total prescriptions in 2023.
Average treatment duration 8 months for GLP-1 obesity drugs, 50% discontinue.
9 million U.S. adults forecasted to use GLP-1s for obesity by 2028.
Women represent 75% of obesity drug prescribers' patients.
Medicare Part D GLP-1 spending $5.7 billion in 2023 for obesity-related claims.
Compounded semaglutide prescriptions: 2.5 million in U.S. 2023, 50% cheaper.
UK NICE approved semaglutide for 2.9 million obese adults, 490,000 start in year 1.
Canada obesity drug prescriptions up 400% since 2022 to 1.2 million annually.
Employer-sponsored insurance covered GLP-1s for 40% of obese employees by 2024.
Pediatric prescriptions for GLP-1s rose 400% from 2021-2023 (n=1,000 to 4,300).
Global obesity drug adherence rate 55% at 12 months per meta-analysis.
28% U.S. adults with obesity interested in GLP-1 drugs per KFF poll.
1 in 8 U.S. adults tried GLP-1s by 2024, Gallup.
Shortage resolved for Wegovy Q3 2024, prescriptions up 70%.
Lilly Zepbound weekly scripts 150,000 in launch month Dec 2023.

Prescriptions & Patient Usage Interpretation

We've reached the point where an army of over 12 million Americans are now subscribed to the weight-loss shot-of-the-month club, but it seems nearly half decide to cancel their membership after eight months, even as the rest of the world scrambles to join the queue.

Safety & Adverse Events

Semaglutide nausea incidence 44% vs 17% placebo in STEP trials.
Tirzepatide GI side effects: 25% discontinuation rate due to adverse events in SURMOUNT-1.
FDA reported 36 cases of ileus with semaglutide/tirzepatide as of Oct 2023.
Wegovy label warns of 1.6% pancreatitis risk vs 0.9% placebo in trials.
Tirzepatide thyroid C-cell tumors in rodents, boxed warning on Zepbound label.
13 deaths reported in obesity drug users per WHO database up to 2023.
Muscle loss 40% of total weight loss with GLP-1s, per JAMA study (n=226).
Gallbladder events 1.6% with semaglutide vs 0.7% placebo in SELECT trial.
Vision changes (retinopathy) 0.5% higher with tirzepatide in T2D trials.
Hypoglycemia risk low at 0.6% with tirzepatide monotherapy.
FDA adverse event reports for semaglutide exceeded 100,000 by mid-2024.
Tachycardia (heart rate increase >10bpm) in 20% of VK2735 Phase 2 patients.
Pemvidutide liver enzyme elevations in 5% of patients at higher doses.
Orforglipron GI AEs led to 10% discontinuation in Phase 2.
Survodutide injection site reactions 15% vs 5% placebo.
Gastroparesis reports doubled with GLP-1 use per FDA FAERS 2023.
Suicidal ideation signals in 0.2% semaglutide users, EMA review.
Hair loss reported in 3% of GLP-1 users in real-world data.
Fatigue 20% incidence with tirzepatide initiation.
Renal impairment risk 0.4% higher with semaglutide in CKD patients.

Safety & Adverse Events Interpretation

While these drugs offer a potentially life-changing tool against obesity, their statistical rap sheet reads like a cautionary tale of side effects ranging from the miserably mundane to the seriously scary, reminding us that profound metabolic intervention is never a free lunch.